Today: 9 June 2026
Rocket Lab stock drops again today: RKLB slides as SpaceX-xAI buzz fades, Mars funding in focus

Rocket Lab stock drops again today: RKLB slides as SpaceX-xAI buzz fades, Mars funding in focus

NEW YORK, Feb 5, 2026, 12:14 (EST) — Regular session underway.

  • Rocket Lab shares dipped in midday trading, continuing a volatile week for space stocks
  • Investors are balancing changing U.S. space-policy signals with the pace of launches and emerging programs
  • Attention now shifts to Rocket Lab’s Feb. 26 earnings and any fresh details on the Neutron rocket schedule

Shares of Rocket Lab Corporation dropped nearly 6% on Thursday, hovering around $69 as the stock continued its recent slide affecting several space-related companies this week. By roughly 12:15 p.m. EST, the Nasdaq-listed stock was down 5.9% at $68.74, with about 11 million shares changing hands. This followed a 10% plunge in the previous session, according to MarketScreener data.

This shift is crucial as Rocket Lab stands as a quick-play proxy for sprawling themes like government space budgets, defense satellites, and the fresh “AI in orbit” trend — all while it ramps up its heavy-lift capabilities. Sentiment around it rarely moves gently; when it shifts, it often does so sharply.

On Tuesday, Elon Musk announced that SpaceX had merged with his AI company xAI, valuing the new combined entity at $1.25 trillion. The news sparked a rally in U.S.-listed space stocks like Rocket Lab, Planet Labs, and AST SpaceMobile. AJ Bell investment director Russ Mould suggested the move might “whet the appetite” for a potential SpaceX IPO. Meanwhile, Seraphim Space CEO Mark Boggett described it as “the strongest validation yet” that space will drive AI’s next wave. Reuters

Investors have also been rethinking longer-term plays linked to NASA science missions. According to Scientific American, a “minibus” spending bill cleared by the House on Jan. 8 has effectively gutted NASA’s Mars Sample Return program, slashing nearly all funding for future phases. Rocket Lab CEO Peter Beck had earlier estimated the company could handle a Mars sample return for $4 billion, targeting a 2031 mission return.

Rocket Lab highlighted its focus on execution and launch cadence. At the end of January, the company marked its 81st Electron mission, completing two launches within eight days. The latest sent a South Korean Earth-observation satellite into orbit from its New Zealand facility. “Two launches in eight days is a strong start to the year,” Beck said then. GlobeNewswire

Neutron remains the key variable for many investors—Rocket Lab’s reusable medium-lift rocket designed for bigger payloads and constellation missions. In January, the company reported that a Stage 1 tank ruptured during a hydrostatic pressure test, which fills the tank with liquid to check its integrity. Rocket Lab is now reviewing test data to determine how this might affect the launch timeline. They also confirmed there was no major damage to their facilities, and production of the next tank is already underway.

Rocket Lab will release its fourth-quarter and full-year 2025 earnings after the U.S. market closes on Feb. 26, the company announced. A conference call is scheduled for 5 p.m. ET that day.

That said, the risks run both ways. Should Neutron face bigger delays than anticipated, or if budget decisions in Washington tighten funding for key science projects, the stock could dive fast—even if Electron continues to perform well.

Traders are zeroing in on one date: Feb. 26. That’s when investors expect more clarity on Neutron’s timeline and hints on how Rocket Lab intends to juggle launch frequency alongside its wider space systems ambitions.

Stock Market Today

  • Dow Jones Rises on Optimism Over U.S.-Iran Deal; Micron and SanDisk Stocks Rebound
    June 9, 2026, 10:02 AM EDT. The Dow Jones Industrial Average climbed Tuesday following President Trump's remarks suggesting a U.S.-Iran agreement could be finalized within "two or three days." This positive geopolitical development boosted market sentiment. Meanwhile, tech stocks Micron Technology and SanDisk gained further momentum, continuing their recent recovery. Investors responded to potential easing of Middle East tensions and improving semiconductor sector outlook. The comments and sector performance provided broad support for the market's advance.

Latest articles

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

9 June 2026
Regentis Biomaterials shares dipped 2 cents to $1.28 premarket after the company announced European surgeon training for its GelrinC knee implant will begin in Q3, marking a key commercial step but leaving investors waiting for revenue proof as the stock trades far below its $8 IPO price.
IREN Stock Approaches $60 as AI Data-Center Bet Hits Key Point

IREN Stock Approaches $60 as AI Data-Center Bet Hits Key Point

9 June 2026
IREN surged 8.9% to $59.19 and was quoted higher premarket after a bitcoin rebound and renewed focus on its pivot to AI cloud infrastructure, but the stock remains exposed to bitcoin swings, heavy spending, and risks tied to its new 800MW South Australia data center project and major contracts with Nvidia and Microsoft.
AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

9 June 2026
AT&T shares edged up to $22.58 pre-market after reaffirming 2026 guidance and a $45B+ shareholder return plan, providing a cash-flow marker as satellite broadband competition looms; the stock remains pressured by SpaceX risks flagged by Oppenheimer, with second-quarter free cash flow seen at $4.0–$4.5B.
GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

9 June 2026
GSK will buy Nuvalent for $10.6 billion in cash, paying a 40% premium, to boost its oncology pipeline ahead of looming HIV drug patent expiries; Nuvalent shares jumped 38.9% premarket while GSK fell 1.4%, with the deal expected to add to GSK sales and profit from 2027 but dilute earnings per share 2026-2028 if it closes in Q3, and final outcome depends on FDA approvals and regulatory clearance.
Dow Jones drops nearly 300 points as Alphabet AI spending plan rekindles tech jitters
Previous Story

Dow Jones drops nearly 300 points as Alphabet AI spending plan rekindles tech jitters

Applied Materials (AMAT) stock snaps back near $300 as Alphabet AI spend stirs chip-equipment trade
Next Story

Applied Materials (AMAT) stock snaps back near $300 as Alphabet AI spend stirs chip-equipment trade

Go toTop